Capital Research Global Investors Biomarin Pharmaceutical Inc Transaction History
Capital Research Global Investors
- $479 Billion
- Q2 2025
A detailed history of Capital Research Global Investors transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Capital Research Global Investors holds 391,879 shares of BMRN stock, worth $22.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
391,879
Previous 9,150,655
95.72%
Holding current value
$22.3 Million
Previous $647 Million
96.67%
% of portfolio
0.0%
Previous 0.15%
Shares
32 transactions
Others Institutions Holding BMRN
# of Institutions
672Shares Held
185MCall Options Held
1.28MPut Options Held
1.1M-
Black Rock Inc. New York, NY22.7MShares$1.29 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.08 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$897 Million0.71% of portfolio
-
Dodge & Cox San Francisco, CA15.1MShares$859 Million0.5% of portfolio
-
Viking Global Investors LP12.3MShares$699 Million2.14% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.6B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...